Comparative Efficacy of Basal-Bolus Versus Premixed Insulin Regimens in Achieving Glycemic Control Among Patients with Type 2 Diabetes Mellitus: A Systemic Review
DOI:
https://doi.org/10.70749/ijbr.v2i02.177Keywords:
T2DM, BSI, PZI, Glycometabolic Management, Insulin Regimes, Self-Monitored Blood Glucose Levels, Insulin Therapy, HypoglycemiaAbstract
Background: T2DM is one of the most prevalent chronic illnesses, requiring effective management to prevent complications. Oral antidiabetic agents are typically needed only in the initial stage to control blood glucose level, while insulin therapy becomes essential as the disease progresses. This includes both basal-bolus and premixed insulin regiments. Therefore, defining an optimal treatment schedule is crucial to improve outcomes in T2DM management and minimize associated attack.
Objective: This systematic review assesses the efficacy and safety of the basal-bolus regimen compared to premixed insulin in treating glycemia in T2DM.
Methods: The study search involved PubMed, EMBASE, Cochrane Library, and Scopus; the search done strictly applied the PRISMA guidelines. A Review of RCTs, cohort studies, and systematic reviews for comparing basal-bolus regimens to the premixed insulin regimens in A-T2DM was done. These were HbA1c, FPG, and PPG. Secondary endpoints were the incidence of hypoglycemia, adherence to therapy, and disease-specific quality of life.
Results: From the above search, we identified 45 studies that meet the inclusion criteria. Daily basal-bolus regimens demonstrated a slightly better reduction in HbA1c, FPG, and PPG than premixed regimens with the trade-offs related to hypoglycemia and regimen complexity. However, basal-bolus regimens are disadvantaged by having more hypoglycemia episodes than the a priori premixed regimens for patients requiring fewer injections.
Conclusion: While basal-bolus regimens give better glycaemic control than premixed ones, the latter are safer and easier to use in some patients. Sources call into question of patient’s characteristics in particular, features of T2DM, the patient’s behavior, and his/her genetic background in order to come up with the most effective and individualized treatment plan more consequently than in any other case.
References
American Diabetes Association. (2020). Standards of medical care in diabetes—2020. Diabetes Care, 43(Supplement 1), S1–S212.
Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., … & Buse, J. B. (2018). Management of hyperglycemia in type 2 diabetes, 2018. Diabetes Care, 41(10), 2669–2701.
DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177-188.
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629-634.
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., … & Umpierrez, G. E. (2020). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocrine Practice, 26(1), 107–139.
Harris, S. B., Kapor, J., Lank, C. N., Willan, A. R., & Houston, T. (2019). Clinical inertia in patients with T2DM requiring insulin in primary care. Diabetes Research and Clinical Practice, 148, 134-142.
Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., … & Sterne, J. A. (2011). The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ, 343, d5928.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 6(7), e1000097.
Owens, D. R., Monnier, L., & Bolli, G. B. (2020). Premixed insulin regimens in diabetes: T2DM. Diabetes Research and Clinical Practice, 170, 108566.
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Canadian Journal of Cardiology, 34(5), 575-584.
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., … & Williams, R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice, 157, 107843.
Wells, G. A., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (2012). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute.
Wexler, D. J., Nathan, D. M., Grant, R. W., Regan, S., & Cagliero, E. (2019). Cognitive and physical function in older adults with diabetes. Journal of Gerontology, 75(7), 1200-1206.
Yki-Järvinen, H. (2019). Insulin therapy in type 2 diabetes. Endocrine Reviews, 40(2), 354-371.
Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2019). Pathophysiology of type 2 diabetes and its treatment policy. Journal of Diabetes Investigation, 10(5), 1-18.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
